<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991834</url>
  </required_header>
  <id_info>
    <org_study_id>MPFabiola</org_study_id>
    <nct_id>NCT01991834</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophylaxis in Gynecologic Laparoscopy</brief_title>
  <official_title>Antibiotic Prophylaxis in Gynecologic Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade do Vale do Sapucai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade do Vale do Sapucai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Laparoscopy is a surgical procedure indicated for most gynecological pathologies and presents
      numerous advantages over laparotomy, among them lower rates of surgical site infection and
      less comorbidity feverish. Despite this, the use of antibiotic prophylaxis is widely accepted
      and performed by most gynecologists. However, there isn't literature evidence to support the
      routine use of antibiotics in the prophylaxis of wound infection on laparoscopic pelvic
      surgery .Therefore, this study will evaluate the need for the use of antibiotic prophylaxis
      in gynecological laparoscopies not including opening hollow viscera.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a clinical, prospective, double-blind, randomized study. 114 women with gynecologic
      disease, in which there is indication of laparoscopic surgical approach, will be
      consecutively select. These women will be allocated in two arms, control and study, where
      control group will use placebo and study will receive intravenous cephazolin. These patients
      will be followed for 30 days according to Centers for Disease Control and Prevention
      criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical site infection</measure>
    <time_frame>30 days</time_frame>
    <description>Patients are followed weekly by a masked surgeon in regard to surgical site infecton (SSI), until the 30th postoperative day. Centers for Disease Control and Prevention's (CDC) criteria and classification were adopted.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Infection Secondary to Surgical Procedure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gynecologic laparoscopy</intervention_name>
    <description>Gynecological laparoscopy without opening hollow viscera.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Cefazolin</arm_group_label>
    <other_name>pelvic laparoscopy</other_name>
    <other_name>gynecologic laparoscopic surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>Intravenous administration of 1 g of cefazolin</description>
    <arm_group_label>Cefazolin</arm_group_label>
    <other_name>Cephazolin</other_name>
    <other_name>Cefazoline</other_name>
    <other_name>Cephazolin Sodium for Injection</other_name>
    <other_name>Kefzol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous administration of saline sterile solution</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with gynecologic disease, undergoing gynecologic laparoscopy without opening
             hollow viscera.

        Exclusion Criteria:

          -  body mass index over 30 Kg/m2

          -  smoking

          -  diabetes type I or II with glycated hemoglobin exceeding 6.5%

          -  patients who are at surgical risk classification of the American Society of
             Anesthesiologists(ASA) as ASA III or higher

          -  refusal to participate

          -  postoperative antibiotic therapy for another indication clinical complication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabiola SM Campos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade do Vale do Sapucai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela F Veiga, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade do Vale do Sapucai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clinicas Samuel Libanio</name>
      <address>
        <city>Pouso Alegre</city>
        <state>Minas Gerais</state>
        <zip>37550-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Santa Paula</name>
      <address>
        <city>Pouso Alegre</city>
        <state>Minas Gerais</state>
        <zip>37550-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade do Vale do Sapucai</investigator_affiliation>
    <investigator_full_name>Fabiola Soares Moreira Campos</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>laparoscopy</keyword>
  <keyword>surgical wound infection</keyword>
  <keyword>antibiotic prophylaxis</keyword>
  <keyword>gynecologic surgical procedures</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

